




RealRate

PHARMACEUTICAL 2015

International Stem Cell CORP
Rank 236 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of International Stem Cell CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 17% points. The greatest weakness of International Stem Cell CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 141% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	3,616
Cost of Goods Sold	1,921
Intangible Assets	2,795
Liabilities, Current	6,858
Liabilities, Non-Current	0
Other Assets	54
Other Compr. Net Income	0
Other Expenses	2,785
Other Liabilities	0
Other Net Income	-3,798
Other Revenues	7,017
Property and Equipment	714
Research and Development	5,386
Selling, General and Administrative Expense	5,605

Output Variable	Value in 1000 USD
Assets	7,179
Liabilities	6,858
Expenses	15,697
Revenues	7,017
Stockholders Equity	321
Net Income	-12,478
Comprehensive Net Income	-12,478
BaseVar	20,274
ECR before Limited Liability	-168%
Economic Capital Ratio	113%